Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Shares Outstanding (Diluted Average) (2019 - 2025)

Allogene Therapeutics' Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $218.8 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 4.59% year-over-year to $218.8 million; the TTM value through Sep 2025 reached $218.8 million, up 4.59%, while the annual FY2024 figure was $194.8 million, 24.14% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $218.8 million at Allogene Therapeutics, up from $217.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $218.8 million in Q3 2025 and bottomed at $132.2 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $145.7 million (2023), against an average of $164.4 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) rose 2.27% in 2023 before it soared 36.65% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $135.8 million in 2021, then rose by 5.39% to $143.1 million in 2022, then rose by 9.63% to $156.9 million in 2023, then rose by 24.14% to $194.8 million in 2024, then grew by 12.31% to $218.8 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Shares Outstanding (Diluted Average) are $218.8 million (Q3 2025), $217.2 million (Q2 2025), and $215.4 million (Q1 2025).